Marinus Pharmaceuticals (MRNS) Set to Announce Earnings on Wednesday

Marinus Pharmaceuticals (NASDAQ:MRNS) will be posting its quarterly earnings results before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. The firm had revenue of $7.19 million for the quarter, compared to the consensus estimate of $7.78 million. During the same quarter in the prior year, the firm earned ($0.76) EPS. On average, analysts expect Marinus Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Marinus Pharmaceuticals Stock Up 0.7 %

NASDAQ MRNS traded up $0.01 during mid-day trading on Thursday, hitting $1.48. The company’s stock had a trading volume of 121,978 shares, compared to its average volume of 1,447,743. The firm has a market capitalization of $81.30 million, a price-to-earnings ratio of -0.57 and a beta of 1.15. The company’s 50 day simple moving average is $7.02 and its 200 day simple moving average is $8.03. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a twelve month low of $1.11 and a twelve month high of $11.26.

Analysts Set New Price Targets

MRNS has been the topic of a number of analyst reports. Robert W. Baird restated a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Tuesday, April 16th. Royal Bank of Canada restated a “sector perform” rating and issued a $3.00 target price (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday, April 15th. Oppenheimer reiterated a “market perform” rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. StockNews.com cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $16.07.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.